Bertilimumab Biosimilar – Anti-CCL11 mAb – Research Grade

Description of Bertilimumab Biosimilar - Anti-CCL11 mAb - Research Grade

Introduction to Bertilimumab Biosimilar

Bertilimumab Biosimilar is a monoclonal antibody (mAb) that targets the chemokine CCL11, also known as eotaxin-1. This biosimilar is a research grade version of the original drug, Bertilimumab, which is currently in clinical trials for the treatment of various inflammatory and autoimmune diseases. In this scientific web content, we will explore the structure, activity, and potential applications of Bertilimumab Biosimilar as an anti-CCL11 mAb.

Structure of Bertilimumab Biosimilar

Bertilimumab Biosimilar is a recombinant humanized IgG1 mAb that is produced in Chinese hamster ovary (CHO) cells. It is composed of two heavy chains and two light chains, with a total molecular weight of approximately 150 kDa. The heavy chains contain four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains contain two constant domains (CL and CL2) and one variable domain (VL). The variable domains of the heavy and light chains are responsible for binding to the target molecule, CCL11.

Activity of Bertilimumab Biosimilar

Bertilimumab Biosimilar specifically binds to CCL11 with high affinity and inhibits its activity. CCL11 is a chemokine that plays a key role in the recruitment and activation of eosinophils, a type of white blood cell involved in the inflammatory response. By binding to CCL11, Bertilimumab Biosimilar prevents it from binding to its receptor, CCR3, on the surface of eosinophils. This leads to a decrease in eosinophil activation and recruitment, thereby reducing inflammation.

In addition to its anti-CCL11 activity, Bertilimumab Biosimilar also has anti-inflammatory effects through the modulation of other immune cells. It has been shown to inhibit the production of pro-inflammatory cytokines, such as IL-6 and TNF-α, and promote the production of anti-inflammatory cytokines, such as IL-10. This dual mechanism of action makes Bertilimumab Biosimilar a promising therapeutic agent for various inflammatory and autoimmune diseases.

Applications of Bertilimumab Biosimilar

As mentioned earlier, Bertilimumab Biosimilar is currently in clinical trials for the treatment of inflammatory and autoimmune diseases. Some of the potential applications of this biosimilar include:

1. Asthma: CCL11 has been shown to play a crucial role in the pathogenesis of asthma. By inhibiting CCL11, Bertilimumab Biosimilar could potentially reduce airway inflammation and improve lung function in patients with asthma.

2. Atopic dermatitis: Atopic dermatitis is a chronic inflammatory skin disease that is characterized by the infiltration of eosinophils. As CCL11 is a major chemoattractant for eosinophils, Bertilimumab Biosimilar could be an effective treatment for this condition.

3. Inflammatory bowel disease (IBD): IBD, including Crohn’s disease and ulcerative colitis, is characterized by chronic inflammation of the gastrointestinal tract. CCL11 has been implicated in the pathogenesis of IBD, and Bertilimumab Biosimilar could potentially reduce inflammation and improve symptoms in patients with IBD.

4. Rheumatoid arthritis (RA): RA is an autoimmune disease that is characterized by chronic inflammation of the joints. CCL11 has been found to be elevated in the synovial fluid of patients with RA, and targeting this chemokine with Bertilimumab Biosimilar could provide a new treatment option for these patients.

Conclusion

In summary, Bertilimumab Biosimilar is a research grade anti-CCL11 mAb that has the potential to be a promising therapeutic agent for various inflammatory and autoimmune diseases. Its unique structure and dual mechanism of action make it a promising candidate for clinical use. Further studies and clinical trials are needed to fully understand the potential applications of this biosimilar and its efficacy in treating different diseases.